Update on treatment of follicular non-Hodgkin's lymphoma: Focus on potential of bortezomib

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 239-251

  Brander, Danielle M ^a   Beaven, Anne W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bortezomib; Follicular lymphoma; Proteasome inhibitor

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TRANSCRIPTION FACTOR; VINCRISTINE;

CANCER GROWTH; CANCER RADIOTHERAPY; COMORBIDITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84885996341     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S23241     Document Type: Review

References (70)

1. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: First Report of the National LymphoCare Study. J Clin Oncol. 2009;27:1202-1208.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
3. Damaj G, Verkarre V, Delmer A, et al. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol. 2003;14:623-629.
4. Goodlad JR, MacPherson S, Jackson R, Batstone P, White J. Extranodal follicular lymphoma: a clinicopathological and genetic analysis of 15 cases arising at non-cutaneous extranodal sites. Histopathology. 2004;44:268-276.
5. Fernandez de Larrea C, Martinez-Pozo A, Mercadal S, et al. Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. Br J Haematol. 2011;153:334-340.
6. Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer. 2010;116:3843-3851.
7. MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282-1290.
8. Wilder RB, et al. Long-term results with radiotherapy for stage I-II. follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51:1219-1227.
9. Brice P, Bastin Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe D'Etude des Lymphomes Folliculaires. J Clin Oncol. 1997;15:1110-1117.
10. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454-1459.
11. Ardeshna KM, Norton A, Hoskin PJ, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516-522.
12. Morton LM, Wang SS, Devesa SS, Hartge P, Welsenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
13. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447-8452.
14. Orlowski RZ. The ubiquitin proteasome pathway from bench to bedside. Hematology Am Soc Hematol Educ Program. 2005:220-225.
15. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349-360.
16. Voorhees PM, Dees EC, O'Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003;9:6316-6325.
17. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
18. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
19. Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998;58:4342-4348.
20. Bagg A. B cells behaving badly: a better basis to behold belligerence in B-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2011;2011:330-335.
21. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22:8590-8607.
22. Ling Y, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G 2-M phase arrest and apoptosis. Mol Cancer Ther. 2002;1:841-849.
23. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998;5:1062-1075.
24. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NF-B/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia. 2004;18:11-17.
25. Strauss SJ, Higginbottom K, Juliger S, et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res. 2007;67:2783-2790.
26. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis J Immunol. 2003;171:88-95.
27. Fisher RI, Berstein SH, Kahl BS, et al. Multicenter Phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867-4874.
28. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667-675.
29. O'Connor OA, Wright J, Moskowitz C, et al. Phase II Clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676-684.
30. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006;24:2105-2112.
31. Di Bella N, Taetle R, Kolibaba K, et al. Results of a Phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115:475-480.
32. O'Connor OA, Portlock C, Moskowitz C, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res. 2010;16:719-726.
33. Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol. 2009;146:652-655.
34. Ribrag V, Tilly H, Casasnovas O, et al. Final results of a randomized Phase 2 multicenter study of two bortezomib schedules in patients with recurrent or refractory follicular lymphoma: Groupe d'Etude des Lymphomes de l'Adulte (GELA) Study FL-05. Blood. 2010; 116:Abstr 768.
35. Smolewski P, Duechler M, Linke A, et al. Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk Res. 2006;30:1521-1529.
36. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized Phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27:5023-5030.
37. Alinari L, White VL, Earl CT, et al. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 2009;1:31-40.
38. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561-1570.
39. Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol. 2010;151:346-353.
40. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009;27:3518-3525.
41. Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011;117:2442-2451.
42. Coiffier B, Osmanov EA, Hong X, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised Phase 3 trial. Lancet Oncol. 2011;12:773-784.
43. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol. 2004;54:343-353.
44. Duechler M, Linke A, Cebula B, et al. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol. 2005;74:407-417.
45. Orlowski RZ, Vorrhess PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105:3058-3065.
46. Cusack JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-k B inhibition. Cancer Res. 2001;61:3535-3540.
47. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136-1144.
48. Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008;22:179-185.
49. Olejniczak SH, Blickwedehl J, Belicha-Villaneuva A, et al. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus-sensitive B-NHL cells. Blood. 2010;116:5605-5614.
50. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005;4:29-296.
51. Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol. 2003;21:4239-4247.
52. Ribrag V, Gisselbrecht C, Haloun C, et al. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized Phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer. 2009;115:4540-4546.
53. Leonard JP, Furman RR, Cheung YK, et al. CHOP-R bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL) [Abstract]. J Clin Oncol. 2007;25:18S.
54. Sehn LH, MacDonald D, Rubin S, et al. Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2011;29:3396-3401.
55. Marcus R, Imrie K, Blech A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
56. Rummel MJ, Al-Batran SE, Kim S, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
57. Robinson KS, Williams ME, va der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-4479.
58. Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The Phase II VERTICAL study. J Clin Oncol. 2011;29:1-9.
59. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/ refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807-2812.
60. Mateos M, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11:934-941.
61. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma. 2010;51:1178-1187.
62. Delforge M, Blade J, Dimopoulos MS, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11:1086-1095.
63. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113-3120.
64. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the Phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895-903.
65. Salles G. Is there a role for bortezomib combinations in the management of patients with follicular lymphoma? J Clin Oncol. 2011;29:1-2.
66. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, Phase 3, non-inferiority study. Lancet Oncol. 2011;12:431-440.
67. Beaven AW, Shea TC, Moore DT, et al. A Phase I study evaluating ibritumomab tiuxetan (Zevalin) in combination with bortezomib (Velcade) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2012;53:254-258.
68. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res. 2010;16: 4094-4104.
69. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
70. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized Phase III Sstudy of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009;114:Abstract 405.